Current Report Filing (8-k)

Date : 02/09/2017 @ 7:47AM
Source : Edgar (US Regulatory)
Stock : Zynerba Pharmaceuticals, Inc. (MM) (ZYNE)
Quote : 6.23  -0.11 (-1.74%) @ 8:00PM

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8—K

 


 

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): February 9, 2017

 


 

ZYNERBA PHARMACEUTICALS, INC.

(Exact Name of Issuer as Specified in Charter)

 


 

Delaware

 

001-37526

 

26-0389433

(State or Other Jurisdiction of
Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

80 W. Lancaster Avenue, Suite 300
Devon, PA 19333

(Address of Principal Executive Offices)

 

(484) 581-7505

(Registrant’s Telephone Number, Including Area Code)

 


 

Check the appropriate box below if the Form 8—K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o       Soliciting material pursuant to Rule 14a—12 under the Exchange Act (17 CFR 240.14a—12)

 

o       Pre—commencement communications pursuant to Rule 14d—2(b) under the Exchange Act (17 CFR 240.14d—2(b))

 

o       Pre—commencement communications pursuant to Rule 13e—4(c) under the Exchange Act (17 CFR 240.13e—4(c))

 

 

 



 

Item 8.01      Other Events.

 

On February 9, 2017, Zynerba Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that the underwriters of its previously announced underwritten public offering of 2.8 million shares of its common stock at $18.00 per share have exercised in full their option to purchase an additional 420,000 shares of common stock at the public offering price less the underwriting discounts and commissions. A copy of this press release is attached hereto as Exhibit 99.1.

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.

 

Document

 

 

 

99.1

 

Press Release dated February 9, 2017.

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: February 9, 2017

 

 

 

 

ZYNERBA PHARMACEUTICALS, INC.

 

 

 

By:

/s/ Suzanne Hanlon

 

Name:

Suzanne Hanlon

 

Title:

Secretary, General Counsel and
Vice President, Human Resources

 

3



 

EXHIBIT INDEX

 

Exhibit
No.

 

Document

 

 

 

99.1

 

Press Release dated February 9, 2017.

 

4


ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE)
Historical Stock Chart

1 Year : From Sep 2016 to Sep 2017

Click Here for more ZYNERBA PHARMACEUTICALS, INC. Charts.

ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE)
Intraday Stock Chart

Today : Monday 25 September 2017

Click Here for more ZYNERBA PHARMACEUTICALS, INC. Charts.

Latest ZYNE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.